RayKnowChina Research Map
Shortlist0

RecruitingDuchenne muscular dystrophyEarly phase 1

Registered title, quoted from ClinicalTrials.gov

Safety and Dystrophin Expression of SPOT-03 in Duchenne Muscular Dystrophy (DMD) Patients

An open trial on Duchenne muscular dystrophy, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai Children's Medical Center上海交通大学医学院附属上海儿童医学中心ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07188012, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 2 years to 7 years; sex: men only

    Registered eligibility fields

  2. Able to tolerate muscle biopsy under anesthesia and have no contraindications to biopsy.

    Inclusion criterion 4

  3. Subjects with a history of major surgeries within 12 weeks prior to the initial infusion or planning to undergo major surgeries (such as scoliosis surgery) during this study.

    Exclusion criterion 17

    Within 6 months prior to the initial infusion, the subjects are exposed to another investigational drug or have participated in an intervention clinical trial.

    Exclusion criterion 19

  4. Bilirubin ≥ 3.0 mg/dL

    Exclusion criterion 10

    Creatinine ≥ 1.8 mg/dL

    Exclusion criterion 11

    Hemoglobin < 8 or > 18 g/dL

    Exclusion criterion 12

  5. Subjects with positive hepatitis B core antibody or hepatitis C antibody or HIV antibody during screening.

    Exclusion criterion 20

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07188012, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • According to the requirements of the region/country and/or IRB/IEC, the patient and/or legal guardian have signed a written informed consent form and are aware of all relevant study content.
  • Boys aged ≥ 2 years to < 8 years and capable of walking independently for at least 10 meters.
  • The medical history includes clinical diagnosis of DMD and confirmed Duchenne mutations using validated genetic testing (MLPA and whole genome sequencing).
  • Able to tolerate muscle biopsy under anesthesia and have no contraindications to biopsy.
  • Heart, liver, lung, and kidney functions are sufficient:
  • The left ventricular ejection fraction (LVEF) should be ≥ 50%;
  • Forced vital capacity (FVC) > 50% of the expected value, and do not require nighttime ventilation;
  • Patient's glomerular filtration rate (GFR)>30 mL/min/1.73 m2

Exclusion Criteria:

  • Complications other than DMD that may cause muscle weakness and/or motor dysfunction.
  • There are severe intellectual disabilities (such as severe autism, severe cognitive impairment, and severe behavioral disorders) that, according to the investigator's judgment, can affect the study.
  • Hospitalization for respiratory failure within 8 weeks prior to screening.
  • Asthma or underlying lung diseases that are poorly controlled, such as bronchitis, bronchiectasis, emphysema, or recurrent infectious pneumonia that investigator believes may affect respiratory function.
  • Severe uncontrolled heart failure (NYHA III-IV), including any of the following conditions:
  • Intravenous administration of diuretics or positive inotropic drugs is required within 8 weeks prior to screening.
  • Hospitalization due to worsening heart failure or arrhythmia within 8 weeks prior to screening.
  • Abnormal laboratory values considered clinically significant:
  • GGT > 3 × upper limit of normal
  • Bilirubin ≥ 3.0 mg/dL
  • Creatinine ≥ 1.8 mg/dL
  • Hemoglobin < 8 or > 18 g/dL
  • White blood cell count > 18,500/μL
  • Arrhythmias that require anti-arrhythmic treatment.
  • Subjects who are undergoing immunosuppressive therapy.
  • Has used other gene therapy, investigational drugs, or any treatment aimed at increasing dystrophin expression.
  • Subjects with a history of major surgeries within 12 weeks prior to the initial infusion or planning to undergo major surgeries (such as scoliosis surgery) during this study.
  • Subjects who are allergic to investigational products or local aesthetic drugs or have a history of severe allergies or genetic allergic reactions.
  • Within 6 months prior to the initial infusion, the subjects are exposed to another investigational drug or have participated in an intervention clinical trial.
  • Subjects with positive hepatitis B core antibody or hepatitis C antibody or HIV antibody during screening.
  • Investigator believes that the presence of any other serious diseases, medical conditions, or chronic drug treatment needs can pose unnecessary risks to gene transfer.

Quoted from ClinicalTrials.gov, NCT07188012, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07188012, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07188012